As health complications and deaths from alcohol use disorder (AUD) increase in the United States, it is critical that people ...

The polygenic score calculated using concordant single-nucleotide variants may be a method to evaluate risk for alcohol use ...

Study represents the first clinical application of CMND-100, the Company’s proprietary drug platform Vancouver, Canada, March 18, 2025 (GLOBE ...

A phase 2 trial shows significant reduction in drinks per drinking day and weekly alcohol craving with low-dose semaglutide. HealthDay News — Low-dose semaglutide seems to reduce craving and certain ...

Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced positive data from an open-label ...

Altimmune plans Phase 2 trials in 2025 for pemvidutide in alcohol use disorder and liver disease, highlighting weight loss ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

Study represents the first clinical application of CMND-100, the Company's proprietary drug platform Vancouver, Canada, March 18, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: ...

Explore the promising potential of Altimmune, Inc.'s Pemvidutide in NASH, AUD, & obesity treatment, with key trials underway.

Evercore ISI likes the expansion of pemvidutide into alcohol liver disease and alcohol use disorder as it adds another leg to the pemvidutide ...

EUR/AUD slipped lower on Friday as uncertainty sparked by U.S. President Donald Trumps tariff war negatively impacted ...